³Ô¹ÏºÚÁÏÍø

Craig joined ³Ô¹ÏºÚÁÏÍø in December 2016. In January 2017 he transitioned to the role of CEO, leading the company’s efforts to advance organ technology to make every organ count.

Prior to joining the company, Craig served as managing director at Siemens Magnet Technology and simultaneously held a role as an executive member of the Siemens Healthcare MRI business between 2010 and 2016. While at Siemens Magnet Technology, Craig applied his expertise in production and research and development to the development of a revolutionary new magnet contained within the World's strongest clinical MRI system, the Siemens MRI 7 Tesla product, MAGNETOM Terra. In addition, he previously held positions at Oxford Instruments, Amersham Plc and GE Healthcare in a variety of management and leadership roles within the in vivo diagnostics sector.

Craig holds an MBA from the University of Warwick Business School and a Bachelor’s of Engineering in Medical Engineering from the University of Liverpool.

Peter is ³Ô¹ÏºÚÁÏÍø Co-Founder and Chief Medical Officer, and has worked with Constantin and the ³Ô¹ÏºÚÁÏÍø team for more than 20 years on the development of ³Ô¹ÏºÚÁÏÍø's normothermic organ perfusion technology. Peter leads ³Ô¹ÏºÚÁÏÍø's pre-clinical and clinical programmes of ³Ô¹ÏºÚÁÏÍø's patented normothermic organ perfusion technology.

Peter is Professor of Transplantation at the University of Oxford and Director of the Oxford Transplant Centre, where he is responsible for the kidney, small bowel and pancreatic transplant programmes. Earlier in his career Peter was Clinical Director of the Transplant Centre at Addenbrooke’s Hospital, Cambridge, one of the UK’s leading liver transplant centres and visiting Assistant Professor of Surgery at Indiana University Medical Centre, USA, where he established their liver transplant programme.

Peter's research interests lie primarily in novel applications of normothermic organ perfusion, ranging from its use for extracorporeal support to preservation and repair prior to transplantation. He has published over 25 papers on the topic of normothermic perfusion, the basis of the ³Ô¹ÏºÚÁÏÍø technology, as well as in the areas of clinical transplantation, immunosuppression, monoclonal antibodies, xenotransplantation, liver perfusion and aspects of general surgery.

Constantin is ³Ô¹ÏºÚÁÏÍø Co-Founder and Chief Technical Officer and has worked with Peter and the ³Ô¹ÏºÚÁÏÍø team for more than 20 years on the development of ³Ô¹ÏºÚÁÏÍø's normothermic organ perfusion technology. Constantin leads ³Ô¹ÏºÚÁÏÍø's technical development programmes.

Constantin is Professor of Biomedical Engineering at the University of Oxford and Director of the Oxford Institute of Biomedical Engineering. Constantin founded and heads the Biomedical Ultrasonics, Biotherapy and Biopharmaceuticals Laboratory (BUBBL), he is also the Director of the Oxford Centre for Drug Delivery Devices (OxCD3).

Constantin's research interests include normothermic organ perfusion, drug delivery, acoustic cavitation and therapeutic ultrasound. Constantin received the 2017 Royal Academy of Engineering Silver Medal and was appointed as a Fellow of the Royal Academy of Engineering in 2019.

Rupa Basu joined ³Ô¹ÏºÚÁÏÍø in April 2022 and leads the company in the role of Global Chief Commercial Officer and President, North America.

She brings over 25 years of MedTech experience to the role, having built successful commercial organizations and supported many product launches in her career. Rupa’s career in US Healthcare began with Bayer Pharmaceuticals where she honed her skills in both clinical and sales roles. She then transitioned to St Jude Medical (now Abbott), progressively taking on leadership positions including leading the Corporate Accounts team and guiding negotiations and implementation of multi-product contracts in GPOs, IDNs, IHNs and multi-hospital systems. Prior to joining ³Ô¹ÏºÚÁÏÍø, she led the commercial and strategic business development of cardiac, neuro and vascular therapies at Biotronik in the US managing multiple P&L entities for the company.

Rupa holds an MBA from Ohio University and a BS in Math, Physics and Economics from Punjab University.

Stephen joined ³Ô¹ÏºÚÁÏÍø in April 2024 as Chief Financial Officer. He is responsible for overseeing accounting, financial planning and analysis, and investor relations.

With a distinguished career spanning the healthcare and medical device industries, Stephen brings a wealth of financial leadership to ³Ô¹ÏºÚÁÏÍø. His most recent role was as Chief Financial Officer of Paragon 28, Inc., a leading medical device company where he successfully led the company through significant growth, including its IPO and follow on public offering that raised over $220 million.

Prior to Paragon 28, Stephen held senior financial positions at BioScrip, Inc. and Zimmer Biomet. He also has several years of Big Four public accounting experience. His financial acumen and strategic thinking have been instrumental in driving business success and maximizing shareholder value.

Stephen holds a B.S. in Accounting from Ball State University and has an in-active CPA license. He is also a seasoned board member, currently serving on the boards of Aclarion, Inc. and Auddia Inc.

David joined ³Ô¹ÏºÚÁÏÍø in July 2024 as Chief HR Officer, bringing a wealth of experience in HR leadership roles within purpose-led organizations, primarily in the life sciences and technology sectors.

Prior to joining ³Ô¹ÏºÚÁÏÍø, David held the position of CHRO at Novacyt, a publicly listed clinical diagnostics company. He spent nine years at Gilead Sciences in several HR leadership roles. Additionally, David has held both specialist and generalist HR roles at organizations such as Amey, Vodafone, EY, and HayGroup (now Korn Ferry). David’s early career was as an organisational psychologist in the Employment service.

In addition to his executive roles, David has served as a Trustee, as a Board Observer, and has been a mentor for a number of early-stage companies. David holds a BA (Hons) in Psychology and a Diploma in Applied Psychology from the University of Nottingham.

Graham joined ³Ô¹ÏºÚÁÏÍø in June 2019, bringing with him extensive experience in leading senior teams within high-growth SMEs. He has a proven track record in implementing financial controls, managing significant change and growth, building operational capability, and driving profitability and cash generation.

Graham's career in life sciences began in 2006, and since then, he has been involved in two IPOs, numerous fundraisings, and complex licensing transactions. His previous roles include Chief Financial Officer at Neuropharm Group plc and then hVIVO plc, where he played a pivotal role in the growth and financial success of both companies. Prior to his career in life sciences, Graham spent 13 years at PricewaterhouseCoopers, gaining valuable experience in audit, tax, consultancy, business process re-engineering, and outsourcing. He also served as Finance & Operations Director at Proxima, where he helped establish the company as a leading UK purchasing services provider.

Graham holds a first-class BSc in Economics and Maths from the University of Bristol.

Katerina joined ³Ô¹ÏºÚÁÏÍø in July 2022, leading the company’s Clinical Affairs and Training initiatives.

Katerina brings more than 20 years of experience in the US med tech industry and prior to joining, worked at Biotronik for 23 years where she held various roles with increasing responsibility in the Clinical Studies and Training and Education departments. Katerina led the Training and Education team to develop and deliver employee and customer programs aligned with business needs and with a focus on quality and accessibility. In her Clinical Studies role Katerina managed numerous IDE Trials, as well as several Post-Approval Trials and Investigator Initiated Clinical Research Studies. Prior to Biotronik, she held a Clinical Research position at Intermedics and was the Medical Physicist at the Nuclear Medicine department of the University Hospital in Brussels.

Katerina has a Master's degree in Physics from the University of Antwerp, Belgium and a Master's degree in Biomedical Engineering from the University of Brussels, Belgium.

Andy Self leads the New Ventures division at ³Ô¹ÏºÚÁÏÍø, responsible for new applications and strategic partnerships for the company’s proprietary technology beyond the field of organ transplantation.

Andy has >25 years’ experience in the Life Sciences sector. Since joining ³Ô¹ÏºÚÁÏÍø in 2014 Andy has held a number of strategic commercial positions within the company with responsibility for growing ³Ô¹ÏºÚÁÏÍø’s customer base in Europe as well as supporting ³Ô¹ÏºÚÁÏÍø’s European and US clinical trials and approval journey. Prior to joining ³Ô¹ÏºÚÁÏÍø Andy worked for Oxford University Innovation (OUI), the technology transfer company of the University of Oxford, with responsibility for the commercialization of life sciences Intellectual Property developed at the University. Prior to joining OUI, Andy worked for the CRO BioFocus (now part of Charles River Laboratories International Inc.), in various roles with increasing responsibility within its scientific and commercial departments.

Andy holds an Honours Degree in Biological Sciences from the University of Birmingham, UK.

Daniel joined ³Ô¹ÏºÚÁÏÍø in August 2014 to lead the research and development of the company’s devices from laboratory to market approval.

Daniel’s career in engineering spans more than 30-years. Prior to joining ³Ô¹ÏºÚÁÏÍø, Daniel worked at University College London (UCL) in the faculty of Brain Science. While at UCL, Daniel designed and manufactured devices for research into human movement and balance, helping patients with Parkinson Disease, Stroke, Cerebral Ataxia and Dementia. Daniel has also held two previous positions in industry: As a Senior Research Engineer At BAE SYSTEMS Advanced Technology Centre, Daniel developed novel microwave components for beam forming networks and radar, pioneering research into the application of CMOS fabrication processes for the manufacture of thin-film planar circuits and micro-electromechanical systems. As Senior Research Engineer at the GEC Marcon Research Centre Daniel’s research focussed predominately on the development of thin-film, high temperature superconducting, filters and duplexers for applications in aviation, mobile telecommunications and radar.

Daniel holds a Bachelor of Engineering in Engineering Systems from Anglia Ruskin University. He completed an apprenticeship at GEC Marconi from 1993 to 1996.

James joined ³Ô¹ÏºÚÁÏÍø in January 2021 as Director of Operations. He has over 15 years experience in operational leadership roles within the Pharmaceutical and Medical Device sectors. Prior to joining ³Ô¹ÏºÚÁÏÍø James worked for Becton Dickinson & Company (BD) as Operational Excellence Manager for Pharmaceutical Systems Advanced Drug Delivery Systems Manufacturing. During James’ 10 years with BD he held roles within Operational Excellence, Manufacturing, Plant Supply Chain, Supply Chain Projects, and Global Supply Chain.

Earlier in his career, he worked at Catalent Pharma, Patheon, and Penn Pharmaceutical Services in a variety of roles within Product Development, Project Management and Operational Excellence.

James holds a First Class Honours Degree in Pharmaceutical Science from London Metropolitan University, and a Masters Degree in Engineering & Management of Manufacturing Systems from Cranfield University. James holds industrial certification as a Lean Six Sigma Green Belt, Lean Leader, Kaizen Leader, and is a Member of the Institute of Management Services.

Arielle joined ³Ô¹ÏºÚÁÏÍø in December 2023 and currently serves as the Vice President of Global Regulatory Affairs responsible for global regulatory activities.

Prior to joining ³Ô¹ÏºÚÁÏÍø, Arielle served as the Director of Regulatory Affairs at LivaNova, Advanced Circulatory Support where she led the global regulatory activities for the business unit. In addition, she has served as a lead reviewer within the Center for Devices and Radiological Health at the U.S. Food and Drug Administration. While at FDA, she was responsible for leading reviews of various Class II and III cardiovascular medical devices. Arielle also brings with her R&D experience from various roles within small and large medical device companies where she focused on the development of cardiovascular devices. Since 2014, Arielle has served as a Lecturer for the Applied Biomedical Engineering program at Johns Hopkins University.

Arielle holds a PhD in Biomedical Engineering from Carnegie Mellon University and a bachelor’s and master’s degree from the University of North Carolina at Chapel Hill.

Jeff Fecho joined ³Ô¹ÏºÚÁÏÍø in July 2024 and currently serves as Vice President, Global Head of Quality, where he oversees all quality management practices and ensures the highest standards for our products and services.

Prior to joining ³Ô¹ÏºÚÁÏÍø, Jeff served as President of Pelican Quality Advisory, LLC, providing strategic quality consulting and assessments to various companies. He brings a wealth of experience in quality leadership, having held executive roles at prominent medical device companies including BD Carefusion, Endologix, St. Jude Medical, and Boston Scientific. Jeff has a proven track record of driving quality excellence and successfully navigating complex regulatory environments.

Jeff holds a Bachelor of Science in Industrial Technology from East Carolina University and a Master of Business Administration from Elon University.

Mike Hess is Senior Vice President of Product Engineering. In this role Mike leads all technical efforts focused on current generation metra device and global field service engineering functions, and chairs the ³Ô¹ÏºÚÁÏÍø Project Review Committee.

Prior to ³Ô¹ÏºÚÁÏÍø, Mike was employed at Medtronic for over three decades, holding various technical and business leadership positions at the company before retiring in 2023. Medtronic develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide.

Mike is also an adjunct professor in Biomedical Engineering at the University of Minnesota.

He has a BS in Biomedical Engineering from Case Western Reserve University and an MS in Software Engineering from the University of St. Thomas. He is an AIMBE fellow, recipient of the IEEE EMBS 2024 Professional Career Achievement Award, and a member of the Medtronic Bakken Society, the highest technical leadership award in the company.